UK: Use is contraindicated.
AU, US: This drug should be used during pregnancy only if the benefit outweighs the risk.

AU TGA pregnancy category: C
US FDA pregnancy category: B

Comment:
-Beta adrenergic blocking agents may cause bradycardia in the fetus.

Animal studies exceeding 100 times the maximum recommended human doses, revealed no embryotoxicity or teratogenicity. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Limited information indicates that this drug is excreted in low levels in maternal milk. It has a short half-life and only moderate renal excretion, so it would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months.

Caution is recommended.

Excreted into human milk: Yes

See references